Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065818 · ClinicalTrials.gov registry record · NA
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01065818 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants.
The verdict
NCT01065818, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during treatment the 18F-FLT PET scan should be given to get the best results. A Positron Emission Tomography (PET) scan is a type of scan that uses a radioactive solution to locate cancer cells inside the body. Using the PET scan, doctors can locate solid tumors and collect information about how "active" the cancer cells are. For this study, a new type of solution, \[F-18\]-fluoro-L-thymidine (FLT), will be used. FLT can detect actively growing tumor, and researchers hope that FLT may be able to help provide information about how well esophagus cancer treatment is working. This information could be used to help predict if the cancer will respond to treatment. All enrolled subjects will receive PET/CT imaging at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy (3 weeks from the start of Neoadjuvant Therapy) prior to the surgery. At each time of the PET/CT procedure, the subject will receive an injection of FLT which is an investigational pharmaceutical labeled with radioactive fluorine. 45-60 mines after the FLT injection, the scan will be performed. Each scan might take 10-15 minutes. Participation in this pilot study will not change the patients normal chemotherapy, radiation treatment, and surgery recommended the patients physician as parts of their standard of care.
Interventions
- DRUG Fluoro-L-Thymidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065818
The ClinicalTrials.gov registry entry for NCT01065818 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoro-L-Thymidine is the first listed.
NCT01065818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065818 about?
NCT01065818 is a clinical study titled "Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET". The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during treatment the 18F-FLT PET scan should be given to get the best results...
What is the current status of trial NCT01065818?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2009-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01065818?
The interventions under investigation include: Fluoro-L-Thymidine (DRUG).
Who is sponsoring clinical trial NCT01065818?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.